Revolutionary Precision: IceCure's XSense Cryoprobes Secure Landmark U.S. Patent

In a monumental stride for medical innovation, IceCure Medical Ltd. (NASDAQ: ICCM), a trailblazer in cryoablation technology, has announced a significant achievement: the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a crucial U.S. patent application covering its next-generation XSense™ Cryoprobes.

This landmark approval solidifies IceCure's intellectual property fortress and underscores its commitment to revolutionizing tumor treatment.

The newly patented XSense™ Cryoprobes represent a quantum leap in the precision and efficacy of cryoablation, a minimally invasive procedure that destroys benign and malignant tumors by freezing them.

What sets XSense™ apart is its ingenious integration of real-time monitoring capabilities directly into the probe. This allows clinicians to observe the formation of the 'ice ball' – the frozen tissue area – with unprecedented clarity and accuracy during the procedure. This enhanced visualization is particularly vital when treating tumors located near sensitive organs or critical structures, ensuring maximum safety and optimal outcomes for patients.

Designed with meticulous attention to detail, the XSense™ system features cryoprobes with a significantly smaller diameter compared to previous generations.

This reduction in size translates directly into less invasive procedures, potentially reducing patient discomfort and recovery times. Beyond size, the technology’s ability to provide instantaneous feedback on the ice ball's growth empowers physicians to make highly informed decisions, meticulously guiding the freezing process to encompass the entire tumor while safeguarding surrounding healthy tissue.

This level of control is paramount in achieving complete tumor destruction and minimizing complications.

Eyal Shamir, Chief Executive Officer of IceCure Medical, emphasized the profound importance of this patent. "Receiving this Notice of Allowance for our XSense™ Cryoprobe technology is a testament to IceCure's unwavering dedication to innovation and our strategic focus on expanding our intellectual property portfolio," said Mr.

Shamir. "This patent significantly strengthens our competitive position and reinforces our leadership in the cryoablation space. We believe XSense™ will play a pivotal role in enhancing the safety and effectiveness of cryoablation across a spectrum of oncology indications, from breast and kidney to lung and bone tumors, ultimately improving patient care globally."

The patent allowance not only validates IceCure's pioneering research and development efforts but also paves the way for the broader commercialization and adoption of the XSense™ system.

As the medical community increasingly seeks less invasive yet highly effective treatment options, technologies like XSense™ are poised to become cornerstones in modern oncology. This achievement marks a thrilling chapter for IceCure Medical, promising a future where advanced, precise, and safer cryoablation is accessible to more patients in their fight against cancer.